1 |
NCT02230176 |
Recruiting |
Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
- Pancreatic Neuroendocrine Carcinoma
|
- Drug: Sunitinib
- Drug: 177Lu-DOTA0-Tyr3-Octreotate
|
Interventional |
Phase 2 |
- Gustave Roussy, Cancer Campus, Grand Paris
- National Cancer Institute, France
- Advanced Accelerator Applications
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the 12 months PFS
- Overall Survival
- Best response
|
80 |
All |
18 Years and older (Adult, Senior) |
NCT02230176 |
2013-004032-30 2013/2043 |
OCCLURANDOM |
February 2015 |
October 2023 |
October 2023 |
September 3, 2014 |
July 12, 2016 |
|
- Gustave Roussy
Villejuif, Val de Marne, France
|
2 |
NCT02595424 |
Recruiting |
Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery |
- Gastric Neuroendocrine Carcinoma
- Intestinal Neuroendocrine Carcinoma
- Pancreatic Neuroendocrine Carcinoma
|
- Drug: Capecitabine
- Drug: Carboplatin
- Drug: Cisplatin
- (and 3 more...)
|
Interventional |
Phase 2 |
- ECOG-ACRIN Cancer Research Group
- National Cancer Institute (NCI)
- Eastern Cooperative Oncology Group
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Incidence of toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- OS
- Response rate (complete response or partial response) by RECIST 1.1
|
126 |
All |
18 Years and older (Adult, Senior) |
NCT02595424 |
EA2142 NCI-2015-00547 NCI-2015-00505 U10CA180820 |
|
November 6, 2015 |
January 1, 2024 |
January 1, 2029 |
November 3, 2015 |
December 11, 2017 |
|
- Mercy Cancer Center-Hot Springs
Hot Springs, Arkansas, United States - Kaiser Permanente-Deer Valley Medical Center
Antioch, California, United States - Sutter Auburn Faith Hospital
Auburn, California, United States - (and 468 more...)
|
3 |
NCT02893930 |
Recruiting |
Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery |
- Pancreatic Neuroendocrine Tumor G1
- Pancreatic Neuroendocrine Tumor G2
- Refractory Pancreatic Neuroendocrine Carcinoma
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective tumor response (complete response + partial response) as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- Progression-free survival (PFS)
- Incidence of adverse events
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02893930 |
NCI-2016-01356 EA2161 U10CA180820 |
|
February 1, 2017 |
August 1, 2019 |
August 1, 2019 |
September 9, 2016 |
April 17, 2018 |
|
- Mayo Clinic Hospital
Phoenix, Arizona, United States - Mayo Clinic in Arizona
Scottsdale, Arizona, United States - CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas, United States - (and 351 more...)
|
4 |
NCT01465659 |
Recruiting |
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery |
- Pancreatic Alpha Cell Carcinoma
- Pancreatic Beta Islet Cell Carcinoma
- Pancreatic Delta Cell Carcinoma
- (and 2 more...)
|
- Drug: temozolomide
- Drug: pazopanib hydrochloride
|
Interventional |
Phase 1 Phase 2 |
- Northwestern University
- Robert H. Lurie Cancer Center
- National Comprehensive Cancer Network
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of dose limiting toxicities in patients treated with this regimen
- Number of patients responding to treatment
- Number of toxicity events noted in patients undergoing this treatment.
- (and 7 more...)
|
39 |
All |
18 Years and older (Adult, Senior) |
NCT01465659 |
NU 11I03 NCI-2011-02939 STU00053541 |
|
November 2011 |
August 2019 |
August 2020 |
November 7, 2011 |
October 26, 2017 |
|
- Northwestern University
Chicago, Illinois, United States - University of Michigan
Ann Arbor, Michigan, United States - Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States - (and 2 more...)
|
5 |
NCT03042780 |
Recruiting |
FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas |
- Gastro-enteropancreatic Neuroendocrine Tumor
- Pancreatic Cancer
- Neuroendocrine Carcinomas of Pancreas
- Islet Cell Carcinoma
|
- Drug: FOLFIRINOX
- Drug: Granulocyte colony-stimulating factor (G-CSF)
|
Interventional |
Phase 2 |
- H. Lee Moffitt Cancer Center and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Radiographic Response Rate (ORR)
- Progression Free Survival (PFS)
- Overall Survival (OS)
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT03042780 |
MCC-18675 |
|
February 1, 2017 |
March 2020 |
March 2021 |
February 3, 2017 |
December 15, 2017 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
6 |
NCT02834013 |
Recruiting |
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
- Acinar Cell Carcinoma
- Adenoid Cystic Carcinoma
- Adrenal Cortex Carcinoma
- (and 82 more...)
|
- Procedure: Biospecimen Collection
- Biological: Ipilimumab
- Biological: Nivolumab
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR) defined as confirmed and unconfirmed complete and partial response
- Incidence of adverse events graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Best response calculated from the sequence of RECIST 1.1 and immune-related response criteria (irRC) objectives
- (and 3 more...)
|
707 |
All |
18 Years and older (Adult, Senior) |
NCT02834013 |
NCI-2016-01041 S1609 U10CA180888 |
|
January 13, 2017 |
August 31, 2020 |
|
July 15, 2016 |
April 17, 2018 |
|
- University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - University of South Alabama Mitchell Cancer Institute
Mobile, Alabama, United States - Anchorage Associates in Radiation Medicine
Anchorage, Alaska, United States - (and 815 more...)
|
7 |
NCT02259725 |
Recruiting |
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors |
- Gastrinoma
- Glucagonoma
- Insulinoma
- (and 6 more...)
|
- Drug: regorafenib
- Other: laboratory biomarker analysis
|
Interventional |
Phase 2 |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFS
- Tumor response rate, evaluated using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee
- Overall survival
- Incidence of adverse events, assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT02259725 |
0S-14-3 NCI-2014-01996 HS-14-00583 P30CA014089 |
|
August 16, 2016 |
August 16, 2019 |
August 16, 2020 |
October 8, 2014 |
April 20, 2017 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States - USC Norris Comprehensive Cancer Center
Los Angeles, California, United States - Seattle Cancer Care Alliance
Seattle, Washington, United States
|
8 |
NCT02820857 |
Recruiting |
Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer |
- Neuroendocrine Carcinomas
|
- Drug: Folfiri-bevacizumab
- Drug: Folfiri
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Proportion of patients alive
|
124 |
All |
18 Years and older (Adult, Senior) |
NCT02820857 |
69HCL14_0442 |
BEVANEC |
September 4, 2017 |
September 4, 2020 |
March 4, 2022 |
July 1, 2016 |
December 18, 2017 |
|
- Service d'Hépato-Gastroenterologie et Oncologie Digestive, Hôpital Sud, CHU d'Amiens
Amiens, France - Service d'Hépatogastroentérologie, CHU d'Angers
Angers, France - Service de Gastroentérologie et Pancréatologie, Hôpital Beaujon, APHP
Clichy, France - (and 17 more...)
|
9 |
NCT03147768 |
Recruiting |
Laser Tissue Welding - Distal Pancreatectomy Sealing Study |
- Pancreatic Tumor, Benign
- Pancreatic Neoplasms
- Pancreatic Adenocarcinoma
- (and 11 more...)
|
- Device: Distal Pancreatectomy Sealing Using LTW
|
Interventional |
Phase 1 |
- Laser Tissue Welding, Inc.
- National Cancer Institute (NCI)
- CHI St. Luke's Health, Texas
|
Industry / NIH / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- PRIMARY EFFICACY AS A SEALANT: Intra-operative blood loss
- SECONDARY SAFETY: Post-operative blood loss requiring return to the operating room
- SECONDARY SAFETY: Prolonged post-operative pancreatic leakage
- SECONDARY SAFETY: Surgical space abscess
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT03147768 |
Phase I - LTW Pancreas Sealing R44CA203052 |
LTW |
May 15, 2017 |
March 2019 |
June 2019 |
May 10, 2017 |
May 11, 2017 |
|
- Baylor CHI St. Luke's Medical Center
Houston, Texas, United States
|
10 |
NCT00830557 |
Recruiting |
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders |
- Islet Cell Tumor
- Pancreatic Cancer
- Pancreatic Disease
|
- Other: medical chart review
- Other: survey administration
- Other: biospecimen collection
|
Observational |
|
- Mayo Clinic
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Collection of clinical data, health and family histories by survey
- Collection of blood and/or tissue, fecal and oral specimens
- Collection of information regarding food preparation and intake by survey
|
7500 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00830557 |
354-06 P50CA102701-08 CDR0000613100 |
|
October 2000 |
September 2022 |
September 2022 |
January 28, 2009 |
September 11, 2017 |
|
- Mayo Clinic Cancer Center
Rochester, Minnesota, United States
|